Radiation plus dostarlimab for post-surgery endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether adding dostarlimab (an immunotherapy medicine) to radiation after surgery can lower cancer returning and improve outcomes. It’s for people with certain endometrial cancers found to have specific genetic/molecular changes and who have stage III/IVA disease after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your cancer is endometrial cancer, and you had full surgical staging showing stage III or stage IVA disease
- Your tumor has one of these: MMR-D, MSI-H, or POLE mutation (tumor testing reports are needed, unless POLE was tested outside the hospital)
- After surgery, you must NOT have measurable remaining disease on imaging (according to RECIST 1.1)
- You must have finished surgery 3 to 12 weeks before starting treatment and be well enough to proceed
- You must have blood test and organ-function levels that meet study limits (including enough white blood cells, platelets, kidney function, and liver enzymes)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether giving a short course of radiation together with chemotherapy can help treat endometrial cancer after surgery. It aims to find a treatment plan that is effective while keeping side effects manageable.
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
This trial tests the drug dostarlimab, alone or with other therapies, given before surgery in people with advanced stage 3 or 4 endometrial cancer. The goal is to see if these treatments shrink the cancer and improve outcomes before the planned operation.
This trial tests a precise type of radiation (stereotactic radiotherapy) given after surgery for endometrial cancer. It aims to improve treatment while reducing side effects.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
This trial tests a drug called dostarlimab (an immunotherapy) given before surgery for early-stage endometrial cancer that has a specific genetic feature (MMRd/MSI-H). The goal is to see if the drug can shrink or eliminate the cancer before standard surgery.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.